LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) announced that three of its abstracts have been accepted for poster presentation at the European Respiratory Society (ERS) Congress 2025, taking place September 27 to October 1 in Amsterdam, The Netherlands. In addition, the company will host an industry-led mini symposium focused on advances in treating autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease.
Key Research Highlights
The presentations will showcase findings on disease burden, treatment efficacy, and diagnostic tools related to aPAP:
- Pulmonary Function and Quality of Life
A study led by Dr. Francesco Bonella of Ruhrlandklinik University Hospital explores the relationship between pulmonary gas transfer, respiratory health-related quality of life, exercise capacity, and surfactant burden in aPAP patients. - Efficacy of Inhaled Molgramostim
Dr. Cormac McCarthy of University College Dublin will present findings on how inhaled molgramostim performs across varying levels of disease severity. - Diagnostic Advancements
TrilliumBiO’s Dr. Eagappanath Thiruppathi will introduce a new dried serum assay designed to detect GM-CSF antibodies, a tool expected to improve diagnostic accuracy for aPAP.
Mini Symposium: Advances in aPAP
Savara will also host an Industry Evening Mini Symposium on September 29, titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis.” The session will feature updates on disease pathophysiology, signs and symptoms, burden of illness, and evolving treatment strategies. Presenters include:
- Dr. Effrosyni D. Manali, National and Kapodistrian University of Athens
- Dr. Maria Molina-Molina, Hospital Universitario de Bellvitge, Spain
- Dr. Maria Kokosi, Royal Brompton Hospital, London
Brian Robinson, M.D., Executive Vice President of Global Medical Affairs at Savara, will chair the session.
Expanding the Dialogue on Rare Lung Diseases
By presenting these studies and leading discussions at ERS 2025, Savara aims to strengthen awareness and advance clinical understanding of autoimmune pulmonary alveolar proteinosis. The company’s research highlights its commitment to improving diagnostics and treatment strategies for patients with this rare and often misunderstood disease.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.